Trial to Compare Diets in Patients With Leukemia or MDS and Prolonged Neutropenia
The trial’s primary objective is to compare the incidence of major infections.
Acute Myeloid Leukemia
Chemotherapy With Antisense Oligonucleotide Oblimersen Improves Disease Free Survival in Older Patients With AML
Researchers sought to determine whether the antisense oligonucleotide oblimersen can be added safely to conventional chemotherapy for older patients with AML.
Gilteritinib Shows Efficacy in Patients With Acute Myeloid Leukemia With Prior Tyrosine Kinase Inhibitor Therapy
Researchers sought to determine whether gilteritinib would have efficacy in patients with relapsed/refractory AML who had received prior TKI therapy.
Venetoclax Combined With FLAG-IDA Yields High Response Rates in Patients With Newly Diagnosed Acute Myeloid Leukemia
Researchers sought to determine whether FLAG-IDA with venetoclax would yield MRD-negative composite complete remission in patients with newly diagnosed AML.
How COVID-19 Lockdown Affected Outcomes of Acute Myeloid Leukemia Patients
The mortality rate was significantly higher in the lockdown phase than in the lockdown-lifted phase.
Most Hospitals Surveyed Did Not Have ‘Lifesaving’ Drug for Acute Promyelocytic Leukemia
Thirty-one percent of hospitals had ATRA immediately available.
Does Adding Leukopheresis to Treatment Improve Survival in Acute Myeloid Leukemia With Leukostasis?
A retrospective analysis sought to determine if adding leukapheresis would improve survival in AML patients with leukostasis.
Acute Myeloid Leukemia: What Your Patients Need to Know
Acute myeloid leukemia (AML) progresses more rapidly than other forms of leukemia. As such, if you or your patient are concerned they may have AML it is important to educate them on the symptoms and risk factors of the disease, as well as how to detect it and what treatments it could entail.
Immunotherapeutic Potential of RNA-Modifying Drugs and MicroRNAs in Acute Myeloid Leukemia
Researchers reviewed epitranscriptomics and the prospects of precision medicines that target AML-associated genes.
CPX-351 May Provide Survival Benefit in Older Patients With High-Risk or Secondary Acute Myeloid Leukemia
The 5-year survival rate was longer with CPX-351 than with conventional chemotherapy.
- Loading...
Loading...
Next post in Hematologic Cancers
Loading... 
Loading...